Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

• DOI: 10.1093/neuonc/noaa104
• Publication Date: 2020-04-23T19:10:37Z
• Authors: Catherine Hanna; Kathreena M Kurian; Karin Williams; Colin Watts; Alan Jackson; Ross Carruthers; Karen Strathdee; Garth Cruickshank; Laurence Dunn; Sara Erridge; Lisa Godfrey; Sarah Jefferies; Catherine McBain; Rebecca Sleigh; Alex McCormick; Marc Pittman; Sarah Halford; Anthony J Chalmers
• Keywords: Olaparib; Tolerability; Temozolomide; PARP inhibitor

The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor. Clinically, PARP inhibitors exacerbate the hematological side effects of TMZ. OPARATIC trial conducted to measure recurrent by assess safety tolerability its combination with